Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PRNP | P04156 | 5/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 3/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979791 | 1.00 | CYP1A2 (0.58) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL6899659 | 0.81 | RXFP1 (0.53) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL2098479 | 0.81 | RXFP1 (0.53) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL5807877 | 0.77 | RXFP1 (0.51) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL4370424 | 0.77 | RXFP1 (0.50) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL10410970 | 0.77 | RXFP1 (0.50) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL2200585 | 0.77 | NCF1 (0.52) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL11326601 | 0.77 | RXFP1 (0.50) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL10411067 | 0.77 | RXFP1 (0.50) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 | |
| SCHEMBL8347789 | 0.77 | PRNP (0.59) | CYP1A2PRNPRXFP1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | claimed |
| CN-104530415-B | A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-01 | — | — | CN | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-101208605-A | New type water-solubility nanocrystalline containing low molecular weight coating agent and preparation method thereof | AGENCY SCIENCE TECH & RES (SG) | 2008-06-25 | — | — | CN | claimed |
| CN-101203761-A | New type water-solubility nanocrystalline containing polymerization coating agent and method for making same | AGENCY SCIENCE TECH & RES (SG) | 2008-06-18 | — | — | CN | claimed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | claimed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | claimed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119095853-A | KRAS inhibitors | 伊莱利利公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-101203761-A | New type water-solubility nanocrystalline containing polymerization coating agent and method for making same | AGENCY SCIENCE TECH & RES (SG) | 2008-06-18 | — | — | CN | disclosed |
| US-6667313-B1 | High affinity and specificity | LIGAND PHARMACEUTICALS INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | HAMANN LAWRENCE G (US) | 2003-08-07 | — | — | US | disclosed |
| EP-1212322-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016133-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0390099-B1 | Polar cephalosporin derivatives and process for their preparation | HOECHST AG (DE) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | AR, SHBG, NR5A1 | CYP1A2 346/4885PRNP 4101/4885RXFP1 344/4885 |
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 3303/4885PRNP 4703/4885RXFP1 935/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | CYP1A2 3303/4885PRNP 4703/4885RXFP1 935/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 3303/4885PRNP 4703/4885RXFP1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.